SCHEMBL5416137

SCHEMBL5416137

CNc1nc(Nc2ccc(Cl)c(Cl)c2)ncc1NC(=O)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ IGF1R P08069 1/20 0.45
▸ STK17A Q9UEE5 2/20 0.44
▸ GRM4 Q14833 1/20 0.44
▸ STK17B O94768 1/20 0.44
▸ LRRK2 Q5S007 5/20 0.43
▸ JAK2 O60674 2/20 0.43
▸ BRD4 O60885 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ EGFR P00533 1/20 0.42
▸ ITK Q08881 1/20 0.42
▸ ALK Q9UM73 3/20 0.42
▸ MET P08581 2/20 0.42
▸ ULK1 O75385 1/20 0.40
▸ PTK2 Q05397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5408198 0.89 HDAC3 (0.48) HDAC3HDAC1HDAC2HDAC6STK17A
SCHEMBL5415948 0.87 HDAC3 (0.49) HDAC3HDAC1HDAC2HDAC6IGF1R
SCHEMBL5415421 0.86 STK17A (0.48) HDAC3HDAC1HDAC2HDAC6STK17A
SCHEMBL5418319 0.86 EGFR (0.45) HDAC3HDAC1HDAC2HDAC6STK17A
SCHEMBL5418427 0.85 HDAC3 (0.47) HDAC3HDAC1HDAC2HDAC6STK17A
SCHEMBL5415300 0.85 BRD4 (0.46) HDAC3HDAC1HDAC2HDAC6STK17A
SCHEMBL5410091 0.84 APEX1 (0.53) HDAC3HDAC1HDAC2HDAC6STK17A
SCHEMBL5413822 0.84 CYP3A4 (0.53) HDAC3HDAC1HDAC2HDAC6STK17A
SCHEMBL5413555 0.83 HDAC3 (0.46) HDAC3HDAC1HDAC2HDAC6STK17A
SCHEMBL5418456 0.83 STK17A (0.47) HDAC3HDAC1HDAC2HDAC6STK17A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 HDAC3 4754/4885HDAC1 3995/4885HDAC2 4239/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 HDAC3 4861/4885HDAC1 4218/4885HDAC2 4513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback